Propanc Biopharma Inc (OTCMKTS: PPCB) has been making a spectacular move up in recet trading from a start point of $0.00389 lows to recent highs over $0.09 per share. During this time PPCB has transformed into a volume leader and one of the top most traded stocks on the entire OTCBB.
PPCB moves up comes on no news and no other known catalysts as of yet but one cannot argue with $2.5 million in dollar volume per day out of nowhere. Something is happening here and we at MCP are all over it.
Propanc Biopharma Inc (OTCMKTS: PPCB) bills itself as a biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body by targeting and eradicating cancer stem cells. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product candidate to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening.
PPCB lead product candidate is PRP, a solution for intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Progressing towards a First-In-Human study, PRP seeks to prevent recurrence and metastasis from solid tumors by targeting and eradicating cancer stem cells. Eighty percent of cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. A report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company’s initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
Earlier this year PPCB entered national phase for two of its key patent applications from its intellectual property portfolio. The first patent application, which entered national phase in July, describes a method to eradicate cancer stem cells, and a second patent application, covering proenzyme compositions for the treatment of solid tumors, recently completed national phase entry mid-July. National phase is a process whereby applicants file a patent application in each individual jurisdiction or country, according to where intellectual property protection is sought. The Company has filed the patent applications in all major global jurisdictions including the US and Europe, as well as key jurisdictions in Asia and South America. Both cover the Company’s lead product candidate, PRP, or use as an anti-cancer stem cell therapy, which is set to enter clinical development.
To Find out the inside Scoop on PPCB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Further, the Company is working with its advisors, to explore ways to restructure and strengthen the Company’s balance sheet to ensure the Company is sufficiently resourced to progress its lead product candidate, PRP, into a first-in-human study in advanced cancer patients.
On August 9, PPCH announced the Company has been selected to present at the prestigious 25th Annual NewsMakers in the Biotech Industry on Friday, September 7th, at 2:00pm, ET, at the Millennium Broadway Hotel and Conference Center in New York.
Hosted by BioCentury, only 48 companies are handpicked to present their stories to institutional investors in the Biotech sector. Last year, more than 500 delegates congregated at NewsMakers, including money managers who controlled more than $600 billion in equity assets, with over $50 billion dedicated to healthcare and $15 billion dedicated to biotech.
“We are very proud to have been selected by BioCentury to present at NewsMakers in the Biotech Industry. It gives us a great opportunity to convey our story to international investors,” said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer. “Our focus will be to present the recent advancements of our lead product candidate, PRP, and its effects against cancer stem cells as a way to control metastasis, which is the main cause of patient death from cancer.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $3.1 million market valuation PPCB has little assets, growing debt and no revenues to date. But there is a lot to get excited about on PPCB, this is a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers. These are all multi-billion dollar markets and any advancements in any of these fields could be big considering the $3.1 total market valuation of Propanc Biopharma. Currently running up the charts on significant dollar volume investors are all over this one. We will be updating on PPCB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PPCB.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in PPCB either long or short and we have not been compensated for this article.